Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
HSTC:PMC's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.65 * Ranked among companies with meaningful Debt-to-EBITDA only.
Pharmedic Pharmaceutical Medicinal Joint Stock Company (HSTC:PMC) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Pharmedic Pharmaceutical Medicinal Joint Stock Company Debt-to-EBITDA Related Terms
Pharmedic Pharmaceutical Medicinal Joint Stock Company Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmedic Pharmaceutical Medicinal Joint Stock Company Debt-to-EBITDA Chart
Pharmedic Pharmaceutical Medicinal Joint Stock Company Annual Data
Trend
Debt-to-EBITDA
Pharmedic Pharmaceutical Medicinal Joint Stock Company Quarterly Data
Debt-to-EBITDA
HSTC:PMC vs IMNPQ: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pharmedic Pharmaceutical Medicinal Joint Stock Company's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmedic Pharmaceutical Medicinal Joint Stock Company Debt-to-EBITDA vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (. 20) EBITDA data.
Pharmedic Pharmaceutical Medicinal Joint Stock Company (HSTC:PMC) has a Debt-to-EBITDA of 0.00 as of . 20. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Pharmedic Pharmaceutical Medicinal Joint Stock Company.
Is Pharmedic Pharmaceutical Medicinal Joint Stock Company's Debt-to-EBITDA too high?
Pharmedic Pharmaceutical Medicinal Joint Stock Company's current Debt-to-EBITDA is 0.00.
How does Pharmedic Pharmaceutical Medicinal Joint Stock Company's Debt-to-EBITDA compare to IMNPQ?
Pharmedic Pharmaceutical Medicinal Joint Stock Company's Debt-to-EBITDA of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-EBITDA is 1.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.65, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Pharmedic Pharmaceutical Medicinal Joint Stock Company. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmedic Pharmaceutical Medicinal Joint Stock Company's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmedic Pharmaceutical Medicinal Joint Stock Company stock overvalued right now?
Pharmedic Pharmaceutical Medicinal Joint Stock Company (HSTC:PMC) has a current Debt-to-EBITDA of 0.00. The current Debt-to-EBITDA is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Pharmedic Pharmaceutical Medicinal Joint Stock Company (HSTC:PMC), the current Debt-to-EBITDA is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pharmedic Pharmaceutical Medicinal Joint Stock Company Business Description
Pharmedic Pharmaceutical Medicinal Joint Stock Company is involved in the production and sales of pharmaceutical products, cosmetics, medical supplies, and other products in the health sector. The company's products include Farzincol Bottle, Farzincol Syrup, Sibemag, Vitamin C 50, Vitamin PP 500, Vitamin PP 50, Nacofar, Cooldrop, Inhaler, Povidine 10% 90ml, Povidine 4% 500, Povidine 10% 8ml, and Povidine 4% 800.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HSTC:PMC has been successfully added to your 
